Search

Displaying results 5321 - 5330 of 7186 in total
  1. Drug

    Mephedrone

    go.drugbank.com/drugs/DB13108
    Investigational

    Mephedrone has been investigated in Alcohol-Related Disorders and Amphetamine-Related Disorders.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    SIG-205

    go.drugbank.com/drugs/DB18548
    Experimental

    SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer

  3. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX. … [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706]

  4. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  5. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.

  6. Drug

    Indopan

    go.drugbank.com/drugs/DB01446
    ExperimentalIllicit

    Indopan (alpha-methyltryptamine) is a stimulant and psychoactive drug which produces effects similar to 3,4-methylenedioxy-N-methylamphetamine (MDMA), despite being structurally dissimilar. … It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.

  7. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.

  8. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  9. Drug

    ND1251

    go.drugbank.com/drugs/DB05132
    Experimental

    ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression.

  10. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein. … It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777]